Literature DB >> 24318862

The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists.

Yang Yang1, Ling Zhang, Heyuan Geng, Yao Deng, Baoying Huang, Yin Guo, Zhengdong Zhao, Wenjie Tan.   

Abstract

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with pathogenic mechanisms that may be driven by innate immune pathways. The goal of this study is to characterize the expression of the structural (S, E, M, N) and accessory (ORF 3, ORF 4a, ORF 4b, ORF 5) proteins of MERS-CoV and to determine whether any of these proteins acts as an interferon antagonist. Individual structural and accessory protein-coding plasmids with an N-terminal HA tag were constructed and transiently transfected into cells, and their native expression and subcellular localization were assessed using Wes tern blotting and indirect immunofluorescence. While ORF 4b demonstrated majorly nuclear localization, all of the other proteins demonstrated cytoplasmic localization. In addition, for the first time, our experiments revealed that the M, ORF 4a, ORF 4b, and ORF 5 proteins are potent interferon antagonists. Further examination revealed that the ORF 4a protein of MERS-CoV has the most potential to counteract the antiviral effects of IFN via the inhibition of both the interferon production (IFN-β promoter activity, IRF-3/7 and NF-κB activation) and ISRE promoter element signaling pathways. Together, our results provide new insights into the function and pathogenic role of the structural and accessory proteins of MERS-CoV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24318862      PMCID: PMC4875403          DOI: 10.1007/s13238-013-3096-8

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  48 in total

1.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

2.  Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist.

Authors:  Ye Ye; Kevin Hauns; Jeffrey O Langland; Bertram L Jacobs; Brenda G Hogue
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses.

Authors:  Xiaobo Lei; Xinlei Liu; Yijie Ma; Zhenmin Sun; Yaowu Yang; Qi Jin; Bin He; Jianwei Wang
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

4.  G0/G1 arrest and apoptosis induced by SARS-CoV 3b protein in transfected cells.

Authors:  Xiaoling Yuan; Yajun Shan; Zhenhu Zhao; Jiapei Chen; Yuwen Cong
Journal:  Virol J       Date:  2005-08-17       Impact factor: 4.099

5.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

6.  Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane.

Authors:  Matthew Frieman; Boyd Yount; Mark Heise; Sarah A Kopecky-Bromberg; Peter Palese; Ralph S Baric
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein.

Authors:  Jose L Nieto-Torres; Marta L Dediego; Enrique Alvarez; Jose M Jiménez-Guardeño; Jose A Regla-Nava; Mercedes Llorente; Leonor Kremer; Shen Shuo; Luis Enjuanes
Journal:  Virology       Date:  2011-04-27       Impact factor: 3.616

8.  Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex.

Authors:  Kam-Leung Siu; Kin-Hang Kok; Ming-Him James Ng; Vincent K M Poon; Kwok-Yung Yuen; Bo-Jian Zheng; Dong-Yan Jin
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

Review 9.  Recent advances in understanding viral evasion of type I interferon.

Authors:  Kathryne E Taylor; Karen L Mossman
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

10.  Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses.

Authors:  Bei Wang; Xueyan Xi; Xiaobo Lei; Xiaoyan Zhang; Sheng Cui; Jianwei Wang; Qi Jin; Zhendong Zhao
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more
  146 in total

1.  The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.

Authors:  Yong Hu; Wei Li; Ting Gao; Yan Cui; Yanwen Jin; Ping Li; Qingjun Ma; Xuan Liu; Cheng Cao
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.

Authors:  Yang Yang; Yao Deng; Bo Wen; Huijuan Wang; Xin Meng; Jiaming Lan; George F Gao; Wenjie Tan
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

Review 3.  Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models.

Authors:  Yanqun Wang; Jing Sun; Airu Zhu; Jingxian Zhao; Jincun Zhao
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 4.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Increased Pathogenicity and Virulence of Middle East Respiratory Syndrome Coronavirus Clade B In Vitro and In Vivo.

Authors:  Yanqun Wang; Jing Sun; Xiaobo Li; Airu Zhu; Wenda Guan; De-Qiang Sun; Jingxian Zhao; Jicheng Huang; Jincun Zhao; Mian Gan; Xuefeng Niu; Jun Dai; Lu Zhang; Zhaoyong Zhang; Yongxia Shi; Shuxiang Huang; Chris Ka Pun Mok; Zifeng Yang; Zhongfang Wang; Wenjie Tan; Yimin Li; Ling Chen; Rongchang Chen; Malik Peiris; Nanshan Zhong
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

6.  Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

Authors:  Kam-Leung Siu; Man Lung Yeung; Kin-Hang Kok; Kit-San Yuen; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Herman Tse; Patrick C Y Woo; Kwok-Yung Yuen; Dong-Yan Jin
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 7.  Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.

Authors:  Anthony R Fehr; Rudragouda Channappanavar; Stanley Perlman
Journal:  Annu Rev Med       Date:  2016-08-26       Impact factor: 13.739

8.  Extensive Positive Selection Drives the Evolution of Nonstructural Proteins in Lineage C Betacoronaviruses.

Authors:  Diego Forni; Rachele Cagliani; Alessandra Mozzi; Uberto Pozzoli; Nasser Al-Daghri; Mario Clerici; Manuela Sironi
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

9.  Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells.

Authors:  Janne Tynell; Veera Westenius; Esa Rönkkö; Vincent J Munster; Krister Melén; Pamela Österlund; Ilkka Julkunen
Journal:  J Gen Virol       Date:  2015-11-24       Impact factor: 3.891

10.  Transgene expression in the genome of Middle East respiratory syndrome coronavirus based on a novel reverse genetics system utilizing Red-mediated recombination cloning.

Authors:  Doreen Muth; Benjamin Meyer; Daniela Niemeyer; Simon Schroeder; Nikolaus Osterrieder; Marcel Alexander Müller; Christian Drosten
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.